Melasma
☆ I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
He ahua noa tenei ka kitea i roto i nga wahine o Ahia i te timatanga o te 40 tau. Ko te reinga porowhita i te whakaahua he tata atu ki te lentigo kaua ki te melasma.
References
Tranexamic acid is a novel treatment option for melasma; however, there is no consensus on its use. This systematic review searched major databases for relevant publications to March 2016. Eleven studies with 667 participants were included. Pooled data from tranexamic acid-only observational studies with pre- and post-treatment Melasma Area and Severity Index (MASI) showed a decrease of 1.60 in MASI after treat?ment with tranexamic acid. The addition of tranexamic acid to routine treatment modalities resulted in a further decrease in MASI of 0.94. These results support the efficacy and safety of tranexamic acid, either alone or as an adjuvant to routine treatment modalities for melasma.
Ina tata nei, kua rongonui a low-fluence Q-switched Nd:YAG (LFQSNY) laser mo te rongoa i te mate pukupuku, ina koa i Ahia. Ko te whakarapopototanga o nga rangahau kanorau he wero, engari ko te ahua o te LFQSNY te ahua whai hua me te haumaru mo te melasma ka whakaritea ki nga rongoa tuku iho. Heoi, ko etahi o nga keehi o te hypopigmentation mottled kua panuitia he paanga taha o te LFQSNY, tera pea na te kaha o te hiko laser. Ko te kaha o te whakamahi i te LFQSNY ka taea hoki te whakapouri mai i te mumura, ina koa ki nga kiri pouri.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
He maha nga wa e kitea ana nga raruraru pigmentation i roto i te tiaki tuatahi. Ko nga momo mate whakapoipoipoata noa ko te post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Kaore e taea te whakatau i te Melasma me te maimoatanga laser mo etahi wa, na te mea he mate e mahia tonutia ana te pigment. Ko te waikawa tranxenemic ka awhina ki te whakapai ake i te whakaheke i te ahua.
○ Maimoatanga
I etahi whenua (e.g. Japan, Korea), kei te waatea te waikawa tranexamic a-waha i runga i te kaute, ka whai hua. Ko te kirikiri melasma me te waikawa tranexamic me te waikawa azelaic ka awhina i tetahi waahanga.
Ka whakamahia pea te Hydroquinone mo te maimoatanga o te hyperpigmentation, engari i aukati te FDA i nga hua OTC kei roto hydroquinone mai i te 2020.
#Tranexamic acid [TRANSINO]
#Laser toning technique (low fluence QS1064 laser)
#Triluma